RAGE signaling inhibition prevents the malignant phenotypes of pancreatic ductal adenocarcinoma cells
Hironori Minami, Seiichi Munesue, Takahiro Araki, Tomokazu Tokoro, Ryohei Takei, Satoshi Takada, Mitsuyoshi Okazaki, Shinichi Nakanuma, Isamu Makino, Yasuhiko Yamamoto, Shintaro Yagi · 2026
Read RAGE signaling inhibition prevents the malignant phenotypes of pancreatic ductal adenocarcinoma cells by Hironori Minami, Seiichi Munesue, Takahiro Araki, Tomokazu Tokoro, Ryohei Takei, Satoshi Takada, Mitsuyoshi Okazaki, Shinichi Nakanuma, Isamu Makino, Yasuhiko Yamamoto, Shintaro Yagi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13243639.txt.
Description
Receptor for advanced glycation end-products (RAGE) is implicated in immune and inflammatory diseases as well as the malignant phenotypes of cancer. Blocking RAGE signaling is thought to reduce its impact on disease states. In this study, we investigated the effect of RAGE signaling inhibitors (inhRAGE) on the malignant phenotypes of pancreatic ductal adenocarcinoma (PDAC). Four PDAC cell lines were used.
Catalog record
| CREATOR | Hironori Minami, Seiichi Munesue, Takahiro Araki, Tomokazu Tokoro, Ryohei Takei, Satoshi Takada, Mitsuyoshi Okazaki, Shinichi Nakanuma, Isamu Makino, Yasuhiko Yamamoto, Shintaro Yagi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |